This webinar will be hosted live and available on-demand
Tuesday, September 19, 2023
11:00 AM Eastern Time
Traumatic brain injury (TBI) is one of the most common neurological disorders, with over 3 million new cases annually in the US alone. Depending on the severity, which ranges from mild to severe, TBI patients are often managed in the emergency room, in the hospital, or in the intensive care unit. There is significant heterogeneity in TBI pathology and expression of subphenotypes, creating a need for precision medicine-based biomarkers as tools for monitoring disease course for individual patients.
In this webinar brought to you by Quanterix, Dr. Kevin Wang will explore how matching the major TBI subphenotypes with precision medicine-based biomarkers is a promising tool for monitoring disease course, predicting patient outcome, and developing new therapies.
Topics to be covered
- Introduction to traumatic brain injury, including the various subphenotypes
- Matching TBI biomarkers to TBI pathology and subphenotypes
- Monitoring TBI disease course and predicting outcomes
- Future applications of TBI biomarkers in drug development and clinical trials
Kevin Wang, PhD